| Dr Michael S Krimigis, OD | |
|
3051 Valley Ave # 102, Winchester, VA 22601-2617 | |
| (540) 450-8504 | |
| (540) 450-8507 |
| Full Name | Dr Michael S Krimigis |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 27 Years |
| Location | 3051 Valley Ave # 102, Winchester, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104960129 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | TA1514 (Maryland) | Secondary |
| 152W00000X | Optometrist | 0618000752 (Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wink Vision | 2264705730 | 3 |
| Myeyedr Optometry Of Maryland Llc | 6002037629 | 61 |
| Wink Vision | 2264705730 | 3 |
| Wink Vision | 2264705730 | 3 |
News Archive
A study published today shows how Indiana University scientists are speeding the path to new treatments for the Zika virus, an infectious disease linked to birth defects in infants in South and Central America and the United States.
Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage.
Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.
Zimmer Holdings, Inc. today announced the opening of a new Zimmer Institute training center at its Trabecular Metal Technology facility in Parsippany, New Jersey. The Zimmer Institute at TMT will be Zimmer's first full-time BioSkills training center outside of the Zimmer Institute's headquarters in Warsaw, Indiana.
Study findings corroborate that patients with schizophrenia who receive outpatient care only during the early stages of their illness have better outcomes than those requiring inpatient hospitalization.
› Verified 3 days ago
| Provider Name | Leesburg Optometry, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1740345750 PECOS PAC ID: 3476638404 Enrollment ID: O20080314000140 |
News Archive
A study published today shows how Indiana University scientists are speeding the path to new treatments for the Zika virus, an infectious disease linked to birth defects in infants in South and Central America and the United States.
Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage.
Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.
Zimmer Holdings, Inc. today announced the opening of a new Zimmer Institute training center at its Trabecular Metal Technology facility in Parsippany, New Jersey. The Zimmer Institute at TMT will be Zimmer's first full-time BioSkills training center outside of the Zimmer Institute's headquarters in Warsaw, Indiana.
Study findings corroborate that patients with schizophrenia who receive outpatient care only during the early stages of their illness have better outcomes than those requiring inpatient hospitalization.
› Verified 3 days ago
| Provider Name | Gainesville Optometry, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1093870099 PECOS PAC ID: 5092890939 Enrollment ID: O20080317000383 |
News Archive
A study published today shows how Indiana University scientists are speeding the path to new treatments for the Zika virus, an infectious disease linked to birth defects in infants in South and Central America and the United States.
Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage.
Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.
Zimmer Holdings, Inc. today announced the opening of a new Zimmer Institute training center at its Trabecular Metal Technology facility in Parsippany, New Jersey. The Zimmer Institute at TMT will be Zimmer's first full-time BioSkills training center outside of the Zimmer Institute's headquarters in Warsaw, Indiana.
Study findings corroborate that patients with schizophrenia who receive outpatient care only during the early stages of their illness have better outcomes than those requiring inpatient hospitalization.
› Verified 3 days ago
| Provider Name | Dulles Optometry Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1699956136 PECOS PAC ID: 6901083401 Enrollment ID: O20110609000817 |
News Archive
A study published today shows how Indiana University scientists are speeding the path to new treatments for the Zika virus, an infectious disease linked to birth defects in infants in South and Central America and the United States.
Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage.
Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.
Zimmer Holdings, Inc. today announced the opening of a new Zimmer Institute training center at its Trabecular Metal Technology facility in Parsippany, New Jersey. The Zimmer Institute at TMT will be Zimmer's first full-time BioSkills training center outside of the Zimmer Institute's headquarters in Warsaw, Indiana.
Study findings corroborate that patients with schizophrenia who receive outpatient care only during the early stages of their illness have better outcomes than those requiring inpatient hospitalization.
› Verified 3 days ago
| Provider Name | Winchester Optometry Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1649417387 PECOS PAC ID: 6901045384 Enrollment ID: O20130614000354 |
News Archive
A study published today shows how Indiana University scientists are speeding the path to new treatments for the Zika virus, an infectious disease linked to birth defects in infants in South and Central America and the United States.
Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage.
Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.
Zimmer Holdings, Inc. today announced the opening of a new Zimmer Institute training center at its Trabecular Metal Technology facility in Parsippany, New Jersey. The Zimmer Institute at TMT will be Zimmer's first full-time BioSkills training center outside of the Zimmer Institute's headquarters in Warsaw, Indiana.
Study findings corroborate that patients with schizophrenia who receive outpatient care only during the early stages of their illness have better outcomes than those requiring inpatient hospitalization.
› Verified 3 days ago
| Provider Name | Myeyedr Optometry Of Virginia, Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1174933691 PECOS PAC ID: 0143448456 Enrollment ID: O20140828001354 |
News Archive
A study published today shows how Indiana University scientists are speeding the path to new treatments for the Zika virus, an infectious disease linked to birth defects in infants in South and Central America and the United States.
Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage.
Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.
Zimmer Holdings, Inc. today announced the opening of a new Zimmer Institute training center at its Trabecular Metal Technology facility in Parsippany, New Jersey. The Zimmer Institute at TMT will be Zimmer's first full-time BioSkills training center outside of the Zimmer Institute's headquarters in Warsaw, Indiana.
Study findings corroborate that patients with schizophrenia who receive outpatient care only during the early stages of their illness have better outcomes than those requiring inpatient hospitalization.
› Verified 3 days ago
| Provider Name | Wink Vision |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1205366333 PECOS PAC ID: 2264705730 Enrollment ID: O20180207000557 |
News Archive
A study published today shows how Indiana University scientists are speeding the path to new treatments for the Zika virus, an infectious disease linked to birth defects in infants in South and Central America and the United States.
Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage.
Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.
Zimmer Holdings, Inc. today announced the opening of a new Zimmer Institute training center at its Trabecular Metal Technology facility in Parsippany, New Jersey. The Zimmer Institute at TMT will be Zimmer's first full-time BioSkills training center outside of the Zimmer Institute's headquarters in Warsaw, Indiana.
Study findings corroborate that patients with schizophrenia who receive outpatient care only during the early stages of their illness have better outcomes than those requiring inpatient hospitalization.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael S Krimigis, OD 1950 Old Gallows Rd, Suite 520, Vienna, VA 22182-3990 Ph: (703) 847-8899 | Dr Michael S Krimigis, OD 3051 Valley Ave # 102, Winchester, VA 22601-2617 Ph: (540) 450-8504 |
News Archive
A study published today shows how Indiana University scientists are speeding the path to new treatments for the Zika virus, an infectious disease linked to birth defects in infants in South and Central America and the United States.
Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage.
Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.
Zimmer Holdings, Inc. today announced the opening of a new Zimmer Institute training center at its Trabecular Metal Technology facility in Parsippany, New Jersey. The Zimmer Institute at TMT will be Zimmer's first full-time BioSkills training center outside of the Zimmer Institute's headquarters in Warsaw, Indiana.
Study findings corroborate that patients with schizophrenia who receive outpatient care only during the early stages of their illness have better outcomes than those requiring inpatient hospitalization.
› Verified 3 days ago
Cheryl K Robson Od Pc Optometrist Medicare: Medicare Enrolled Practice Location: 905 Cedar Creek Grade, Suite 100, Winchester, VA 22601 Phone: 540-665-0541 Fax: 540-665-8286 | |
National Vision Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2530 S Pleasant Valley Rd, Winchester, VA 22601 Phone: 540-773-6595 | |
Allegany Optometry Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2028 S Pleasant Valley Rd, Winchester, VA 22601 Phone: 540-722-3217 Fax: 540-722-3219 | |
Michael J Deiboldt, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 420 W Jubal Early Dr Ste 200, Winchester, VA 22601 Phone: 540-662-2700 Fax: 540-662-8801 | |
Dr. Iris L. Flores, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 675 Adams Rd, Winchester, VA 22603 Phone: 540-336-3364 | |
Phillip D. Rhoads, Od, Pc. Optometrist Medicare: Medicare Enrolled Practice Location: 40b Weems Ln, Winchester, VA 22601 Phone: 540-662-4463 Fax: 540-662-4460 |